EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Trastuzumab-Induced Cardiotoxicity: When and How Much Should We Worry?

Haoyi Zheng iD, Syed S Mahmood iD, Omar K Khalique, Huichun Zhan iD

JCO Oncology Practice · 2024-08 · 20 (8) · 1055-1063

DOI: 10.1200/op.23.00816 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JCO Oncology Practice, 2024-08. Verfasst von Haoyi Zheng und 3 weiteren Autor:innen. Beteiligte Einrichtung: CardioOncology Service, Saint Francis Hospital & Heart Center, Roslyn, NY. Hauptthemen laut MEDLINE: Cardiotoxicity, Trastuzumab. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 58 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This review critically analyzes the incidence of trastuzumab-induced left ventricular systolic dysfunction and congestive heart failure (CHF), distinguishing between cases with and without prior anthracycline exposure. It highlights the fact that the elevated risk of trastuzumab-induced cardiotoxicity is closely associated with prior anthracycline exposure. In the absence of prior anthracycline exposure, the incidence rates of trastuzumab-induced cardiotoxicity, particularly CHF (ranging from 0% to 0.5%), are largely comparable with those reported in the general population, especially when reversibility is taken into account. Current cardiac surveillance recommendations during trastuzumab treatment have not yet adapted to the increasing adoption of nonanthracycline treatment strategies and the associated low risk of cardiotoxicity. We propose a refined monitoring protocol to reduce the frequency of cardiac evaluations for low-risk to moderate-risk patients, especially those receiving nonanthracycline treatments. By focusing on patients at high risk or those with prior anthracycline exposure, this strategy seeks to optimize the cost-effectiveness of cardiac care in oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CardiotoxicityTrastuzumabHumansAntineoplastic Agents, ImmunologicalAnthracyclinesHeart Failure

Substanzen

TrastuzumabAntineoplastic Agents, ImmunologicalAnthracyclines

Autor:innen und Institutionen

  • CardioOncology Service, Saint Francis Hospital & Heart Center, Roslyn, NY.
  • Division of Cardiovascular Imaging, Saint Francis Hospital & Heart Center, Roslyn, NY.
  • Department of Medicine, Stony Brook School of Medicine, Stony Brook, NY.
  • Medical Service, Northport Veterans Affairs Medical Center, Northport, NY.

ORCID-Profile: Haoyi Zheng, Syed S Mahmood, Huichun Zhan

Zitieren

APA

Zheng, H., Mahmood, S. S., Khalique, O. K., & Zhan, H. (2024). Trastuzumab-Induced Cardiotoxicity: When and How Much Should We Worry?. JCO Oncology Practice, 20(8), 1055-1063. https://doi.org/10.1200/op.23.00816

Vancouver

Zheng H, Mahmood SS, Khalique OK, Zhan H. Trastuzumab-Induced Cardiotoxicity: When and How Much Should We Worry?. JCO Oncology Practice. 2024;20(8):1055-1063. doi:10.1200/op.23.00816

BibTeX
@article{Zheng2024,
  author = {Zheng, Haoyi and Mahmood, Syed S and Khalique, Omar K and Zhan, Huichun},
  title = {Trastuzumab-Induced Cardiotoxicity: When and How Much Should We Worry?},
  journal = {JCO Oncology Practice},
  year = {2024},
  volume = {20},
  number = {8},
  pages = {1055--1063},
  doi = {10.1200/op.23.00816}
}
Kostenlos starten →